Cannabinoid

Cannabis plant
#Cannabinoid #Clinical trials #Drug development #Drug discovery

Agreement will speed up cannabinoid drug development

Oxford Cannabinoid Technologies (OCTP) and Evotec have entered into a service agreement to expedite the development of OCTP’s lead compound, OCT461201, a selective cannabinoid receptor Type 2 agonist, towards Phase I clinical trials. This Phase I clinical trial will be aimed at demonstrating the safety and tolerability of the drug… Read More

#News